Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
TEST:
BluePrint
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Agendia
Type:
Laboratory Developed Test
Related tests:
‹
MammaPrint (2)
TargetPrint®
TheraPrint® test
MammaPrint (2)
TargetPrint®
TheraPrint® test
›
Details
Evidence
News
Search handles
@MVanMeterMD
Search handles
@MVanMeterMD
Filter by
Latest
1year
MammaPrint and BluePrint tests provide accurate results for thousands of women. Regardless of age.* #SGBCC2023 #breastcancer *MammaPrint® FFPE is CE-marked, and FDA-cleared for 18 years or older. ()
1 year ago
MammaPrint • BluePrint
over1year
Join Agendia at #EBCC13 in Barcelona! Please stop by booth #B3 to discuss the latest data on #MammaPrint and #BluePrint, our comprehensive genomic #breastcancer tests. ()
over 1 year ago
MammaPrint • BluePrint
almost2years
#CedarsSinaiCancer at #ASCO22. Dr. Alice Chung will be presenting “Identification of transcriptional changes with #MammaPrint and BluePrint in early-stage breast cancer after neoadjuvant #chemotherapy.” @ASCO @CedarsSinaiMed @CSCancerCare @AGiulianoMD #Breastcancer ()
almost 2 years ago
Clinical
|
MammaPrint • BluePrint
almost3years
ICYMI - the recorded @ASBrS Breakfast Symposia April 30th supported by @Agendia featuring @WhitworthMD & @william_audehmd discussing #MammaPrint + #BluePrint #bcsm https://t.co/bkpCcTs0ky (@KBHock90)
almost 3 years ago
MammaPrint • BluePrint
3years
Join the @Agendia team for an @ASBrS virtual breakfast symposium this Fri 4/30 at 9:00a est @WhitworthMD @william_audehmd A Case-Based Discussion of Integrating MammaPrint and BluePrint into Treatment Planning for Patients with Early Stage Breast Cancer https://t.co/GDPRyRt6AE (@KBHock90)
3 years ago
Clinical
|
MammaPrint • BluePrint
over3years
Pat Whitworth, MD @WhitworthMD #NashvilleBreastCenter #SABCS20 #BreastCancer #Cancer #Research NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype. View full video here: https://t.co/cJYS0NT1T7 (@Agendia)
over 3 years ago
Video
|
MammaPrint • BluePrint
over3years
NBRST trial: preoperative MammaPrint and BluePrint breast cancer subtype Pat Whitworth, MD @WhitworthMD #NashvilleBreastCenter #SABCS20 #BreastCancer #Cancer #Research Link To FULL Video: https://t.co/3TKMv2ss1L (@oncologytube)
over 3 years ago
Video
|
MammaPrint • BluePrint
over3years
lost both mom & sister to mTNBC. Dx in 2016, 6mo after my sister death,I was on a HER2+ treatment plan til my thorough @baptisthealthSF #MiamiCancerInstitute oncologist Sara Garrido used @Agendia #MammaPrint & #BluePrint 💙My #breastcancer was #triplenegative GRATEFUL #iamhere 🙏🏾 (@breasttalkever)
over 3 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
MammaPrint • BluePrint
over3years
@curijoey discusses approach on predicting benefit from pertuzumab, based on abstract from Dr. Krop @DanaFarber - APHINITY and BluePrint molecular subtype. #SABCS20 #bscm (@MVanMeterMD)
over 3 years ago
BluePrint
|
Perjeta (pertuzumab)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login